Skip to main content
Fig. 6 | Cancer Cell International

Fig. 6

From: LncRNA MEG8 promotes NSCLC progression by modulating the miR-15a-5p-miR-15b-5p/PSAT1 axis

Fig. 6

MiR-15a-5p and miR-15b-5p inhibit NSCLC progression by targeting PSAT1 in vitro. a The interaction of miR-15a/b-5p and PSAT1 3′ UTR was identified by bioinformatic analysis using Targetscan (http://www.targetscan.org/vert_72/). b The luciferase activities of wild type PSAT1 (PSAT1 WT) and PSAT1 with the miRNA-binding site mutant (PSAT1 MUT) were determined by luciferase reporter gene assays in the A549 cells treated with control mimic (miR-NC), miR-15a-5p mimic, or miR-15b-5p mimic, respectively. c The protein expression of PSAT1and GAPDH was tested by Western blot analysis in the A549 and H1299 cells treated with control inhibitor (inhibitor NC), miR-15a-5p inhibitor, or miR-15b-5p inhibitor, respectively. d The mRNA expression of PSAT1 was measured by qPCR in the A549 cells transfected with control siRNA (NC-siRNA) or PSAT1 siRNA (PAST1-siRNA). eg The A549 cells were treated with control inhibitor (Ctrl), miR-15a/b-5p inhibitors, or co-treated with PSAT1 siRNA (PAST1-siRNA) and inhibitors of miR-15a/b-5p, respectively. e The cell viability was analyzed by CCK-8 assays in the cells. f The cell proliferation was tested by EdU assays in the cells. g The cell migration and invasion were examined by transwell assays in the cells. Data are presented as mean ± SD. Statistic significant differences were indicated: *P < 0.05, **P < 0.01, #P < 0.05

Back to article page